Two Sigma Advisers’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Two Sigma Advisers’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,268	Closed	-$48K	–	2938
2022 Q1	$48K	Sell	1,268 -737	-37%	-$25.5K	﹤0.01%	2595
2021 Q4	$113K	Sell	2,005 -6,936	-78%	-$466K	﹤0.01%	2395
2021 Q3	$646K	Sell	8,941 -1,269	-12%	-$97.1K	﹤0.01%	1821
2021 Q2	$978K	Buy	10,210 +6,490	+174%	+$717K	﹤0.01%	1652
2021 Q1	$550K	Buy	+3,720	New	+$674K	﹤0.01%	1979
2020 Q3	–	Sell	-1,227	Closed	-$216K	–	2680
2020 Q2	$216K	Buy	+1,227	New	+$205K	﹤0.01%	2227

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Two Sigma Advisers's NBSE Position: Q2 2022 in Review

Two Sigma Advisers sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2022, closing a stake of 1,268 shares — an estimated $48K sold.

Two Sigma Advisers first reported a position in NBSE in Q2 2020 and held it in 6 quarters. The position peaked at $978K in Q2 2021. 43 funds tracked by Wall St. Rank hold NBSE as of Q2 2022.

Two Sigma Advisers reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 1,268 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $48K.
Two Sigma Advisers first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Two Sigma Advisers's NeuBase Therapeutics, Inc. Common Stock position peaked at $978K in Q2 2021.
43 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.